Janssen Biotech Offers up to $1Bn to Irish Biotech for a Bowel Inflammation Drug
Janssen Biotech and Theravance Biopharma will develop together a drug to treat bowel inflammation diseases like ulcerative colitis and Crohn&8217;s disease. Janssen BiotechÂhas set its eyes on a...
View ArticleJ&J takes option on Theravances JAK drug in $1bn deal
TD1473 has potential treating ulcerative colitis Crohn’s and IBD patients
View ArticleTheravance J&J Ink $1B Deal for Inflammatory Intestinal Drug
Phase 2b3 study in ulcerative colitis and phase 2 study in Crohn's disease to begin in 2018
View ArticleBrain Gut Both Crucial in Psychotherapy for Chronic Digestive Disorders
For patients with irritable bowel syndrome IBS Crohn's disease and other chronic digestive diseases attention to the brain is as important as the gut researchers say in a February 3 online article in...
View ArticleJanssen and Theravance in IBD Drug Pact
Janssen Biotech part of pharma and consumer goods giant Johnson & Johnson has entered into a global development and commercialization agreement with Theravance Biopharma Ireland for new...
View ArticlePOC Testing Evaluated for Fecal Calprotectin
Ulcerative colitis UC and Crohn's disease CD are the two most prevalent forms of inflammatory bowel disease IBD with the...
View ArticleMedical cannabis significantly safer for elderly with chronic pain than Opioids
American Associates BenGurion University of the Negev The new study published in The European Journal of Internal Medicine found cannabis therapy is safe and efficacious for elderly patients who are...
View ArticleShire's Crohn's HAE candidates granted special development designations
A priority review status was given by Health Canada to Shire's marketing application for SHP643 or lanadelumab which is bei More
View ArticleShires SHP647 bags another orphan badge
US regulators have awarded orphan drug status to Shire's investigational therapy SHP647 for the treatment of paediatric patients with moderately to severely active Crohn's disease.
View ArticleCrohn's Progression Unchanged Despite Advanced Therapies
Despite advances in the treatment of Crohn's disease 5year outcomes are similar to those from 20 years ago a new study showed. Medscape Medical News
View ArticleCelgene Spinout Celularity Raises $250 Million To Develop Placental Cells To...
Celularity a company spun out of biotech giant Celgene announced this morning it has raised $250 million with the aim of developing cells from placentas to attack tumors and to treat Crohns disease. In...
View ArticleSetpoint Medical Inc Medical Equipment Deals and Alliances Profile Report...
SummarySetPoint Medical Inc. SetPoint Medical is a biotechnology company that develops bioelectronic therapies for the treatment of inflammatory autoimmune diseases. The company employs a scientific...
View ArticleTiGenix NV TIG Medical Equipment Deals and Alliances Profile Report Updated...
SummaryTiGenix NV TiGenix is a biopharmaceutical company that develops and commercializes novel therapeutics. Its product portfolio includes AlloCSC01 AlloCSC02 Cx611 and Cx601. The company develops...
View ArticleVedolizumab Emerges as Option in IBD After AntiTNF Failure
The management of antiTNFresistant patients is an important clinical challenge but new data suggest that vedolizumab helps mucosal healing in Crohn's disease and ulcerative colitis. Medscape Medical News
View ArticleScientists from CedarsSinai and Emulate Produce Human Intestinal Lining That...
Findings Have Potential to Advance Personalized Treatments for Gastrointestinal Diseases Investigators have demonstrated how cells of a human intestinal lining created outside an individuals body...
View ArticleCTP13 biosimilar infliximab is comparable to reference infliximab and...
PANTS study shows that CTP13 is an efficacious therapy option when investigating personalised approaches to antiTNF therapy VIENNA&8211;BUSINESS WIRE&8211;Twelvemonth data from the Personalised...
View ArticlePsoriasis drug also effective at reducing aortic inflammation
Ustekinumab sold under the name Stelara is approved by the U.S. Food and Drug Administration to treat psoriasis psoriatic arthritis and Crohn's Disease. Researchers wanted to know if the benefits of...
View Articlesterna biologicals Reports Phase 2a Study Data Demonstrating Efficacy of Its...
Data presented at the 13th Congress of ECCO European Crohn's and Colitis Organisation. SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active...
View ArticleNew IBD Guidelines Aim to Simplify Care
The European Crohn's and Colitis Organisation and the European Society of Gastrointestinal and Abdominal Radiology have joined forces to update recommendations. Medscape Medical News
View ArticleCrohn's Disease Study Indicates Positive Results For Celltrion's Biosimilar...
NewsThe results indicate that the clinical effectiveness safety and immunogenicity of CTP13 biosimilar infliximab in patients with Crohns disease is comparable to those treated with reference...
View Article